Efficacy of cabergoline in uncured (persistent or recurrent) cushing disease after pituitary surgical treatment with or without radiotherapy

Endocrine Practice

Volumn 16, Issue 6, 2010, Pages 968-976

  Lila, Anurag R ^a   Gopal, Raju A ^a   Acharya, Shrikrishna V ^a   George, Joe ^a   Sarathi, Vijaya ^a   Bandgar, Tushar ^a   Menon, Padma S ^a   Shah, Nalini S ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; LIOTHYRONINE; PROLACTIN; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADOLESCENT; ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL EVALUATION; CUSHING DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE SURGERY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOPHYSIS SURGERY; LIOTHYRONINE BLOOD LEVEL; LOW DOSE DEXAMETHASONE SUPPRESSION SERUM CORTISOL; MALE; MEASUREMENT; MIDNIGHT SERUM CORTISOL; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTIN BLOOD LEVEL; RADIOTHERAPY; RECURRENT DISEASE; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ERGOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952422784     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10031.OR     Document Type: Article

References (20)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137-195.
2. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454-2462. (Pubitemid 352008503)
3. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab. 2008;93:358-362. (Pubitemid 351246675)
4. Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab. 2008;4:560-568.
5. Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab. 2007;92:172-179. (Pubitemid 46067527)
6. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158:91-99. (Pubitemid 351211045)
7. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2462. (Pubitemid 38619889)
8. Miyoshi T, Otsuka F, Takeda M, et al. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest. 2004;27:1055-1059.
9. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P. Use of cabergoline in persisting Cushing's disease [in French]. Ann Endocrinol (Paris). 2006;67:353-356.
10. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest. 1999;22:860-865. (Pubitemid 30083180)
11. Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res. 2004;62:300-305. (Pubitemid 40069629)
12. Gopal R, Bandgar T, Menon P, Shah N. Remission in Cushing disease with cabergoline. Ann Saudi Med. 2008;28:224-225.
13. Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94:223-230.
14. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540. (Pubitemid 351656485)
15. Estrada J, García-Uria J, Lamas C, et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2001;86:5695-5699. (Pubitemid 33152610)
16. Carrasco CA, Coste J, Guignat L, et al. Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease. J Clin Endocrinol Metab. 2008;93:4728-4734.
17. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007;92:4123-4129. (Pubitemid 350074721)
18. John M, Lila AR, Bandgar T, Menon PS, Shah NS. Diagnostic efficacy of midnight cortisol and midnight ACTH in the diagnosis and localisation of Cushing's syndrome. Pituitary. 2010;13:48-53.
19. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens. 2000;14(suppl 1):S47-S50. (Pubitemid 30406520)
20. de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94:1118-1124.